Compare Vanguard Dividend Appreciation Index Fund ETF (VIG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Dividend Appreciation Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Dividend Appreciation Index Fund ETF trades at $239.88, while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc pays a 2.89% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VIG | ZTS | |
|---|---|---|
52-Week High | $246.61 | $150.61 |
52-Week Low | $210.70 | $71.91 |
Market Cap | — | $30.29B |
Sector | — | Health |
Enterprise Value | — | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VIG trades at $240.11, down 0.79% on the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF focuses on dividend growth, with a dividend of $1.00 scheduled for June 2026. Recent news highlights its role in retirement portfolios and comparisons with peers like SCHD and DGRO, emphasizing its defensive tech exposure and lower yield strategy.
The outlook for VIG hinges on its dividend growth approach amid market volatility. Opportunities include steady income appeal for long-term investors, while risks involve underperformance if high-yield alternatives gain favor or economic conditions pressure dividend sustainability.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
